Menu
GWAS Study

Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study.

Zazuli Z, de Jong C, Xu W et al.

34834585 PubMed ID
GWAS Study Type
608 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ZZ
Zazuli Z
DJ
de Jong C
XW
Xu W
VS
Vijverberg SJH
MR
Masereeuw R
PD
Patel D
MM
Mirshams M
KK
Khan K
CD
Cheng D
OB
Ordonez-Perez B
HS
Huang S
SA
Spreafico A
HA
Hansen AR
GD
Goldstein DP
DA
de Almeida JR
BS
Bratman SV
HA
Hope A
KJ
Knox JJ
WR
Wong RKS
DG
Darling GE
KA
Kitchlu A
VH
van Haarlem SWA
VD
van der Meer F
VL
van Lindert ASR
TH
Ten Heuvel A
BJ
Brouwer J
RC
Ross CJD
CB
Carleton BC
ET
Egberts TCG
HG
Herder GJM
DV
Deneer VHM
MD
Maitland-van der Zee AH
LG
Liu G
Chapter II

Abstract

Summary of the research findings

This study aims to evaluate genetic risk factors for cisplatin-induced nephrotoxicity by investigating not previously studied genetic risk variants and further examining previously reported genetic associations. A genome-wide study (GWAS) was conducted in genetically estimated Europeans in a discovery cohort of cisplatin-treated adults from Toronto, Canada, followed by a candidate gene approach in a validation cohort from the Netherlands. In addition, previously reported genetic associations were further examined in both the discovery and validation cohorts. The outcome, nephrotoxicity, was assessed in two ways: (i) decreased estimated glomerular filtration rate (eGFR), calculated using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) and (ii) increased serum creatinine according to the Common Terminology Criteria for Adverse Events v4.03 for acute kidney injury (AKI-CTCAE). Four different Illumina arrays were used for genotyping. Standard quality control was applied for pre- and post-genotype imputation data. In the discovery cohort (n = 608), five single-nucleotide polymorphisms (SNPs) reached genome-wide significance. The A allele in rs4388268 (minor allele frequency = 0.23), an intronic variant of the BACH2 gene, was consistently associated with increased risk of cisplatin-induced nephrotoxicity in both definitions, meeting genome-wide significance (β = -8.4, 95% CI -11.4--5.4, p = 3.9 × 10-8) for decreased eGFR and reaching suggestive association (OR = 3.9, 95% CI 2.3-6.7, p = 7.4 × 10-7) by AKI-CTCAE. In the validation cohort of 149 patients, this variant was identified with the same direction of effect (eGFR: β = -1.5, 95% CI -5.3-2.4, AKI-CTCAE: OR = 1.7, 95% CI 0.8-3.5). Findings of our previously published candidate gene study could not be confirmed after correction for multiple testing. Genetic predisposition of BACH2 (rs4388268) might be important in the development of cisplatin-induced nephrotoxicity, indicating opportunities for mechanistic understanding, tailored therapy and preventive strategies.

608 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

608
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Canada
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.